Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DICHLORPHENAMIDE vs AZOPT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
Treatment of increased intraocular pressure in chronic open-angle glaucoma,Secondary glaucoma,Preoperatively in acute angle-closure glaucoma,Off-label: Treatment of familial periodic paralysis,Off-label: Management of altitude sickness
Open-angle glaucoma,Ocular hypertension
25-50 mg orally twice daily.
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 m L/min).
Dichlorphenamide is not extensively metabolized; it is excreted unchanged in urine.
Not significantly metabolized; primarily excreted unchanged in urine via renal tubular secretion.
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
90-95% bound to plasma proteins, primarily albumin.
Approximately 33% bound to plasma proteins (mainly albumin).
0.2-0.3 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid.
Oral: approximately 80-100% (well absorbed); bioavailability not defined for parenteral routes as not typically given.
Ocular bioavailability is not quantified due to local administration; systemic bioavailability after topical ocular dosing is approximately 70% via nasolacrimal absorption.
Cr Cl <50 m L/min: not recommended; Cr Cl 50-80 m L/min: 25 mg once daily; Cr Cl >80 m L/min: no adjustment.
No dosage adjustment required for systemic absorption is minimal. However, use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential metabolite accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: avoid use.
No dosage adjustment required for systemic absorption is minimal. Use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Not established; safety and efficacy not determined in children.
Approved for children ≥2 years: one drop in the affected eye(s) twice daily. For children <2 years: safety and efficacy not established.
Start at 25 mg once daily; monitor renal function and electrolytes.
No specific dose adjustment required. Monitor for ocular irritation and systemic effects, as elderly patients may be more sensitive to adverse reactions such as hypotension or fatigue.
None.
None
Metabolic acidosis: Can occur, especially in patients with renal impairment or electrolyte disturbances.,Hypokalemia: Risk may increase due to bicarbonate loss and metabolic acidosis.,Sulfonamide allergy: Cross-sensitivity possible; caution in patients with history of sulfonamide hypersensitivity.,Renal impairment: Use with caution; may accumulate and worsen acidosis.,Hepatic impairment: Caution due to risk of hepatic encephalopathy.,Drug interactions: May increase effects of other carbonic anhydrase inhibitors, furosemide, and decrease effects of lithium.,Pregnancy: Weigh risks vs benefits; not recommended.,Lactation: Excreted in milk; avoid breastfeeding.
Sulfonamide allergy (cross-reactivity possible),Corneal endothelial damage (risk increased with low endothelial cell count),Bacterial keratitis (with concomitant use of topical corticosteroids or ocular trauma),Contaminated dropper tip may cause ocular infections
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal impairment (e.g., anuria, severe nephropathy),Severe hepatic disease,Hepatic encephalopathy,Hypokalemia (uncorrected),Metabolic acidosis (uncorrected),Adrenal insufficiency,Hyperchloremic acidosis,Pregnancy (relative contraindication),Lactation (relative contraindication)
Hypersensitivity to brinzolamide or any sulfonamides,Severe renal impairment (Cr Cl <30 m L/min) or hyperchloremic acidosis
Avoid high-dose aspirin or salicylates; may increase toxicity. Limit alcohol intake to reduce risk of metabolic acidosis. No specific food restrictions but maintain adequate hydration to prevent renal calculi. Avoid cranberry juice if prone to kidney stones.
No significant food interactions known. However, avoid excessive salt intake if using systemic carbonic anhydrase inhibitors; for AZOPT, ocular use minimizes systemic effects, but caution in patients with electrolyte imbalances.
Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced fetal weight at doses similar to human therapeutic doses. First trimester exposure may carry a risk of teratogenicity; second and third trimester risks include possible metabolic acidosis and electrolyte disturbances in the fetus.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in rabbits and 20 mg/kg/day in rats. However, due to potential for fetal harm (systemic carbonic anhydrase inhibition causing acidosis), use only if clearly needed. First trimester: avoid if possible; second/third trimesters: monitor for maternal acidosis.
It is not known whether dichlorphenamide is excreted in human breast milk. The M/P ratio is unknown. Due to the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug.
It is not known if brinzolamide is excreted in human milk. In animal studies, brinzolamide was detected in milk of lactating rats. Caution is advised; consider risk vs benefit. M/P ratio: unknown.
No specific dose adjustments for pregnancy are established. However, due to pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance), careful monitoring of drug effect and tolerability is recommended. Dose may need individualized titration.
No specific dose adjustments recommended; however, due to potential for increased systemic absorption during pregnancy (increased blood volume and ocular changes), monitor intraocular pressure closely. Use the lowest effective dose. Pharmacokinetic changes: unknown; adjust based on clinical response.
Dichlorphenamide is a carbonic anhydrase inhibitor used for primary open-angle glaucoma and familial periodic paralysis. Monitor serum potassium and perform baseline/periodic blood counts due to risk of hypokalemia and bone marrow suppression. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. Can cause metabolic acidosis; use cautiously in patients with respiratory acidosis or COPD. Dose adjustment required in renal impairment. May increase urate levels; avoid in gout unless urate-lowering therapy is used.
AZOPT (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor used for lowering intraocular pressure in ocular hypertension or open-angle glaucoma. Shake well before use; may cause transient blurred vision. Use with caution in sulfonamide allergy patients. Monitor for corneal edema and electrolyte disturbances in prolonged use.
Take exactly as prescribed; do not skip doses to prevent glaucoma progression.,Report any signs of bleeding, bruising, fever, or sore throat immediately.,May cause drowsiness; avoid driving or operating heavy machinery until effects known.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol and aspirin-containing products to reduce risk of metabolic acidosis.,Drink plenty of fluids to prevent kidney stones; maintain adequate hydration.,Notify doctor if you have liver disease, kidney stones, or breathing problems.,This may increase blood sugar; monitor if diabetic.,Taste disturbances or altered sense of taste may occur and are usually reversible.
Shake the bottle vigorously before each use.,Remove contact lenses before instilling and wait at least 15 minutes before reinserting.,Apply pressure to the tear duct (punctal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not touch the dropper tip to any surface to avoid contamination.,May cause temporary blurred vision; avoid driving or operating machinery until vision clears.,Report any eye pain, redness, or vision changes to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DICHLORPHENAMIDE vs AZOPT, answered by our medical review team.
DICHLORPHENAMIDE is a Carbonic Anhydrase Inhibitor that works by Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.. AZOPT is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DICHLORPHENAMIDE and AZOPT depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DICHLORPHENAMIDE is: 25-50 mg orally twice daily.. The standard adult dose of AZOPT is: One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DICHLORPHENAMIDE and AZOPT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DICHLORPHENAMIDE is classified as Category C. Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced. AZOPT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in ra. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.